Trends in the use of pre-operative radiation for adenocarcinoma of the pancreas in the United States

被引:4
作者
Burke, Erin E. [1 ]
Marmor, Schelomo [1 ,2 ]
Portschy, Pamela R. [1 ]
Virnig, Beth A. [2 ]
Cho, Lawrence C. [3 ]
Tuttle, Todd M. [1 ]
Jensen, Eric H. [1 ]
机构
[1] Univ Minnesota, Dept Surg, 420 Delaware St SE,Mayo Mail Code 195, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Dept Radiat Oncol, Minneapolis, MN 55455 USA
关键词
IMPROVED SURVIVAL; CHEMOTHERAPY; THERAPY; CHEMORADIATION; CANCER; CHEMORADIOTHERAPY; RESECTION; FLUOROURACIL; EPIDEMIOLOGY; SURVEILLANCE;
D O I
10.1111/hpb.12400
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundThe benefit and timing of radiation therapy (RT) for patients undergoing a resection for pancreatic adenocarcinoma remains unclear. This study identifies trends in the use of radiation over a 10-year period and factors associated with the use of pre-operative radiation, in particular. MethodsThe Surveillance, Epidemiology and End Results registry was used to identify patients aged 18years with pancreatic adenocarcinoma who underwent a surgical resection between 2000 and 2010. Logistic regression was used to identify time trends and factors associated with the use of pre-operative radiation. ResultsThe overall use of radiation decreased with time among the 8474 patients who met the inclusion criteria. However, the use of pre-operative radiation increased from 1.8% to 3.9% (P0.05). Factors significantly associated with receipt of pre-operative radiation were younger age, treatment in more recent years and having an advanced T-stage tumour. The 5-year hazard of death was significantly less for those who received pre-operative radiation versus surgery alone [hazard ratio (HR) 0.64, 95% confidence interval (CI) 0.55-0.74] and for those who received post-operative radiation versus surgery alone (HR 0.69, 95% CI 0.65-0.73). DiscussionThe use of pre-operative radiation significantly increased during the study period. However, the overall use of pre-operative radiation therapy remains low in spite of the potential benefits.
引用
收藏
页码:542 / 550
页数:9
相关论文
共 20 条
[1]   FAILURE TO ADHERE TO PROTOCOL SPECIFIED RADIATION THERAPY GUIDELINES WAS ASSOCIATED WITH DECREASED SURVIVAL IN RTOG 9704-A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AND CHEMORADIOTHERAPY FOR PATIENTS WITH RESECTED ADENOCARCINOMA OF THE PANCREAS [J].
Abrams, Ross A. ;
Winter, Kathryn A. ;
Regine, William F. ;
Safran, Howard ;
Hoffman, John P. ;
Lustig, Robert ;
Konski, Andre A. ;
Benson, Al B. ;
Macdonald, John S. ;
Rich, Tyvin A. ;
Willett, Christopher G. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (02) :809-816
[2]   Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration [J].
Tara M. Breslin ;
Kenneth R. Hess ;
Dana B. Harbison ;
Marina E. Jean ;
Karen R. Cleary ;
Alan P. Dackiw ;
Robert A. Wolff ;
James L. Abbruzzese ;
Nora A. Janjan ;
Christopher H. Crane ;
J. Nicolas Vauthey ;
Jeffrey E. Lee ;
Peter W. T. Pisters ;
Douglas B. Evans .
Annals of Surgical Oncology, 2001, 8 (2) :123-132
[3]   Chemoradiation Therapy Sequencing for Resected Pancreatic Adenocarcinoma in the National Cancer Data Base [J].
Colbert, Lauren E. ;
Hall, William A. ;
Nickleach, Dana ;
Switchenko, Jeffrey ;
Kooby, David A. ;
Liu, Yuan ;
Gillespie, Theresa ;
Lipscomb, Joseph ;
Kauh, John ;
Landry, Jerome C. .
CANCER, 2014, 120 (04) :499-506
[4]   Role of Neoadjuvant Therapy in the Multimodality Treatment of Older Patients with Pancreatic Cancer [J].
Cooper, Amanda B. ;
Holmes, Holly M. ;
des Bordes, Jude K. A. ;
Fogelman, David ;
Parker, Nathan H. ;
Lee, Jeffrey E. ;
Aloia, Thomas A. ;
Vauthey, Jean-Nicolas ;
Fleming, Jason B. ;
Katz, Matthew H. G. .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2014, 219 (01) :111-120
[5]   Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo Clinic experience (1975-2005) [J].
Corsini, Michele M. ;
Miller, Robert C. ;
Haddock, Michael G. ;
Donohue, John H. ;
Farnell, Michael B. ;
Nagorney, David M. ;
Jatoi, Aminah ;
McWilliams, Robert R. ;
Kim, George P. ;
Bhatia, Sumita ;
Iott, Matthew J. ;
Gunderson, Leonard L. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) :3511-3516
[6]  
DOUGLASS HO, 1987, CANCER-AM CANCER SOC, V59, P2006
[7]   Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head [J].
Evans, Douglas B. ;
Varadhachary, Gauri R. ;
Crane, Christopher H. ;
Sun, Charlotte C. ;
Lee, Jeffrey E. ;
Pisters, Peter W. T. ;
Vauthey, Jean-Nicolas ;
Wang, Huamin ;
Cleary, Karen R. ;
Staerkel, Gregg A. ;
Charnsangavej, Chusilp ;
Lano, Elizabeth A. ;
Ho, Linus ;
Lenzi, Renato ;
Abbruzzese, James L. ;
Wolff, Robert A. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) :3496-3502
[8]   Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages [J].
Gillen, Sonja ;
Schuster, Tibor ;
zum Bueschenfelde, Christian Meyer ;
Friess, Helmut ;
Kleeff, Joerg .
PLOS MEDICINE, 2010, 7 (04)
[9]   Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy [J].
Golcher, H. ;
Brunner, T. ;
Grabenbauer, G. ;
Merkel, S. ;
Papadopoulos, T. ;
Hohenberger, W. ;
Meyer, T. .
EJSO, 2008, 34 (07) :756-764
[10]   Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: Results of a study from the surveillance, epidemiology, and end results (SEER) registry data [J].
Hazard, Lisa ;
Tward, Jonathan D. ;
Szabo, Aniko ;
Shrieve, Dennis C. .
CANCER, 2007, 110 (10) :2191-2201